Neuropathie bei Diabetes und Prädiabetes: Neue Erkenntnisse zur Früherkennung, Pathogenese und Behandlung

Die diabetische Neuropathie (DN) umfasst eine Vielzahl klinischer Manifestationen, die das somatische und/oder autonome Nervensystem betreffen, im Rahmen des Diabetes auftreten und auf keine anderen Ursachen einer peripheren Neuropathie zurückzuführen sind [1]. Die DN ist Prädiktor für neuropathische Fußulzera und erhöhtes Mortalitätsrisiko [1] [2]. Leider bleibt sie nach wie vor unterdiagnostiziert und -therapiert [2]. Um dem multidisziplinären Aspekt der DN mit dem Ziel einer rechtzeitigen Diagnose und Therapie gerecht zu werden, bedarf es einer möglichst intensiven Zusammenarbeit u.a. von Allgemeinärzten, Diabetologen, Schmerztherapeuten, Neurologen, Urologen, Gastroenterologen und Psychologen [1]. Seit über 40 Jahren ist es unser Ziel, auf die klinische Relevanz dieser häufigen, jedoch weiterhin unterschätzten chronischen Komplikation des Diabetes hinzuweisen und einen Beitrag im Sinne eines holistischen Ansatzes zur Früherkennung, Prädiktion, Prävention und Therapie sowie zu besserem Verständnis der Pathomechanismen zu leisten.

Publication History

Article published online:
17 December 2025

• Literatur

• 1 Ziegler D, Keller J, Maier C. et al. Diabetic Neuropathy. Exp Clin Endocrinol Diabetes 2025;
• 2 Ziegler D, Tesfaye S, Spallone V. et al. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations. Diabetes Res Clin Pract 2022; 186: 109063
• 3 Herder C, Roden M, Ziegler D. Novel insights into sensorimotor and cardiovascular autonomic neuropathy from recent-onset diabetes and population-based cohorts. Trends Endocrinol Metab 2019; 30: 286-298
• 4 Ziegler D, Bönhof GJ, Strom A. et al. GDS group. Progression and regression of nerve fibre pathology and dysfunction early in diabetes over 5 years. Brain 2021; 144: 3251-3263
• 5 Zaharia OP, Strassburger K, Strom A. et al. German Diabetes Study Group. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 2019; 7: 684-694
• 6 Maalmi H, Herder C, Bönhof GJ. et al. GDS Group. Differences in the prevalence of erectile dysfunction between novel subgroups of recent-onset diabetes. Diabetologia 2022; 65: 552-562
• 7 Ziegler D, Behler M, Schroers-Teuber M. et al. Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes. BMJ Open 2015; 5: e006559
• 8 Kück J-L, Bönhof GJ, Strom A. et al. for the GDS group. Impairment in baroreflex sensitivity in recent-onset type 2 diabetes without progression over 5 years. Diabetes 2020; 69: 1011-1019
• 9 Strom A, Strassburger K, Ziegler D. et al. GDS Group. Changes over 10 years in peripheral nerve function in people with well-controlled type 2 diabetes and those with normal glucose tolerance. Neurology 2025; 104: e213780
• 10 Ziegler D, Herder C, Papanas N. Neuropathy in prediabetes. Diabetes Metab Res Rev 2023; e3693
• 11 Bönhof GJ, Herder C, Strom A. et al. Emerging biomarkers, tools, and treatments for diabetic polyneuropathy. Endocr Rev 2019; 40: 153-192
• 12 Bierhaus A, Fleming T, Stoyanov S. et al. Methylglyoxal modification of Na(v)1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 2012; 18: 926-933
• 13 Strom A, Strassburger K, Schmuck M. et al. GDS Group. Interaction between magnesium and methylglyoxal in diabetic polyneuropathy and neuronal models. Mol Metab 2021; 43: 101114
• 14 Singh AK, Bernabucci M, Dvorak NM. et al. Sensory neuron-expressed FGF13 controls nociceptive signaling in diabetic neuropathy models.. J Clin Invest 2025; 135: e183749
• 15 Bönhof GJ, Strom A, Püttgen S. et al. Patterns of cutaneous nerve fibre loss and regeneration in type 2 diabetes with painful and painless polyneuropathy. Diabetologia 2017; 60: 2495-2503
• 16 Bönhof GJ, Strom A, Jung T. et al. Cutaneous carbonyl stress is associated with nerve dysfunction in recent-onset type 2 diabetes. Diabetes Care 2025; 48: 251-258
• 17 Maalmi H, Strom A, Petrera A. et al. GDS Group. Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy. Diabetologia 2023; 66 (03) 579-589
• 18 Schlesinger S, Herder C, Kannenberg JM. et al. General and abdominal obesity and incident distal sensorimotor polyneuropathy: Insights into inflammatory biomarkers as potential mediators in the KORA F4/FF4 cohort. Diabetes Care 2019; 42: 240-247
• 19 Herder C, Zhang S, Wolf K. et al. Environmental risk factors of incident distal sensorimotor polyneuropathy: Results from the prospective population-based KORA F4/FF4 study. Sci Total Environ 2023; 858 (03) 159878
• 20 Nguyen PBH, Garger D, Lu D. et al. Interpretable multimodal machine learning (IMML) framework reveals pathological signatures of distal sensorimotor polyneuropathy. Commun Med (Lond) 2024; 4: 265
• 21 Ziegler D, Thorand B, Strom A. et al. Association of transketolase polymorphisms with diabetic polyneuropathy in the general population: The KORA F4 study. Diabetes Metab Res Rev 2024; 40: e3834
• 22 Kwiatkowska KM, Garagnani P, Bonafé M. et al. High-resolution whole-genome DNA methylation revealed unique signatures of painful diabetic neuropathy. Diabetes 2025; db240930
• 23 Bönhof GJ, Strom A, Apostolopoulou M. et al. High-intensity interval training for 12 weeks improves cardiovascular autonomic function but not somatosensory nerve function and structure in overweight men with type 2 diabetes. Diabetologia 2022; 65: 1048-1057
• 24 Ziegler D, Low PA, Litchy WJ. et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: The NATHAN 1 Trial. Diabetes Care 2011; 34: 2054-60
• 25 Ziegler D, Hidvégi T, Gurieva I. et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care 2010; 33: 839-841
• 26 Ziegler D, Duan WR, An G. et al. A randomized double-blind, placebo- and active-controlled study of T-type calcium channel blocker ABT-639 in diabetic patients with peripheral neuropathic pain. Pain 2015; 156: 2013-2020